Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
PCSK9 encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. Additionally we are shipping PCSK9 Kits (72) and PCSK9 Proteins (61) and many more products for this protein.
Showing 10 out of 154 products:
Human Polyclonal PCSK9 Primary Antibody for ChIP, IHC (p) - ABIN268772
Cohen, Pertsemlidis, Kotowski, Graham, Garcia, Hobbs: Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. in Nature genetics 2005
Show all 10 references for ABIN268772
Human Polyclonal PCSK9 Primary Antibody for IHC (p), WB - ABIN374535
Lambert, Ancellin, Charlton, Comas, Pilot, Keech, Patel, Sullivan, Cohn, Rye, Barter: Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. in Clinical chemistry 2008
Show all 3 references for ABIN374535
Human Polyclonal PCSK9 Primary Antibody for EIA, WB - ABIN453778
McNutt, Kwon, Chen, Chen, Horton, Lagace: Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. in The Journal of biological chemistry 2009
Show all 3 references for ABIN453778
Human Polyclonal PCSK9 Primary Antibody for IHC, ELISA - ABIN185371
Lalanne, Lambert, Amar, Chétiveaux, Zaïr, Jarnoux, Ouguerram, Friburg, Seidah, Brewer, Krempf, Costet: Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells. in Journal of lipid research 2005
Show all 2 references for ABIN185371
Human Polyclonal PCSK9 Primary Antibody for FACS, IHC (p) - ABIN652320
Shioji, Mannami, Kokubo, Inamoto, Takagi, Goto, Nonogi, Iwai: Genetic variants in PCSK9 affect the cholesterol level in Japanese. in Journal of human genetics 2004
Show all 2 references for ABIN652320
Human Polyclonal PCSK9 Primary Antibody for FACS, IHC (p) - ABIN391505
Abifadel, Varret, Rabès, Allard, Ouguerram, Devillers, Cruaud, Benjannet, Wickham, Erlich, Derré, Villéger, Farnier, Beucler, Bruckert, Chambaz, Chanu, Lecerf, Luc, Moulin, Weissenbach, Prat, Krempf et al.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. ... in Nature genetics 2003
Show all 2 references for ABIN391505
Human Polyclonal PCSK9 Primary Antibody for IF (p), IHC (p) - ABIN761831
Jia, Song, Yang, Ma, Li, Lu, Cao, Zhang, Zhu, Wang, Leng, Cao, Du, Xu: Effects of Tanshinone IIA on the modulation of miR‑33a and the SREBP‑2/Pcsk9 signaling pathway in hyperlipidemic rats. in Molecular medicine reports 2016
Human Polyclonal PCSK9 Primary Antibody for EIA, WB - ABIN569616
Kwon, Lagace, McNutt, Horton, Deisenhofer: Molecular basis for LDL receptor recognition by PCSK9. in Proceedings of the National Academy of Sciences of the United States of America 2008
Low LDL cholesterol levels due to PCSK9 and HMGCR (show HMGCR Antibodies) variants had no causal effect on high risk of Alzheimer's disease, vascular dementia, any dementia, or Parkinson's disease; however, low LDL cholesterol levels may have a causal effect in reducing the risk of Alzheimer's disease.
conditions that cause ER stress regardless of their ability to dysregulate ER Ca(2 (show CA2 Antibodies)+) inhibit PCSK9 secretion, thereby reducing PCSK9-mediated LDLR (show LDLR Antibodies) degradation and promoting LDLR (show LDLR Antibodies)-dependent hepatic cholesterol uptake.
Even though LDLR (show LDLR Antibodies)-R410S and LDLR (show LDLR Antibodies)-WT were similar in levels of cell surface and total receptor and bound equally well to LDL or extracellular PCSK9, the LDLR (show LDLR Antibodies)-R410S was resistant to exogenous PCSK9-mediated degradation in endosomes/lysosomes and showed reduced LDL internalization and degradation relative to LDLR (show LDLR Antibodies)-WT.
Lipid therapy today and tomorrow: anti-PCSK9
First human antibodies were recently approved as the first immunotherapeutic agents for the treatment of severe hypercholesterolemia and in patients with statin intolerance. An additional PCSK9 antibody is presently being studied in phase III clinical trials.[review]
Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds to low-density lipoprotein (LDL) receptors leading to their degradation in the liver. Inhibition of PCSK9 leads to an increase in LDL receptors and as a result to a reduction of LDL cholesterol in blood. [review]
Furthermore, the effect of reduction of LDL-C by proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and by the cholesteryl ester transfer protein (CETP (show CETP Antibodies)) inhibitor anacetrapib on cardiovascular events is currently being investigated in large clinical outcome study programs. [review]
Further information on long-term efficacy, tolerability and cost-effectiveness of PCSK9 inhibition and possibilities of implementation in the healthcare system are awaited from ongoing clinical outcome trials, such as FOURIER, ODYSSEY OUTCOMES, SPIRE 1 (show SPIRE1 Antibodies) and 2 involving more than 70,000 high-risk patients. [review]
The 2 or 4week subcutaneous therapy with the recently approved antibodies alirocumab and evolocumab for inhibition of proprotein convertase subtilisin-kexin type 9 (PCSK9) reduces low-density lipoprotein cholesterol (LDL-C) in addition to statins and ezetimibe by 50-60 %. [review]
study provides the first evidence that GPC3 (show GPC3 Antibodies) can modulate the PCSK9 extracellular activity as a competitive binding partner to the LDLR (show LDLR Antibodies) in HepG2 cells.
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor (show LDLR Antibodies) Degradation.
PCSK9 increases hepatic lipid and lipoprotein production via apoE (show APOE Antibodies)- and LDLR (show LDLR Antibodies)-dependent mechanisms
Podocyte damage triggers marked inductions in plasma PCSK9, and knockout of Pcsk9 ameliorates dyslipidemia in a mouse model of nephrotic syndrome.
polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating PCSK9.
binding of PCSK9 to GRP94 (show HSP90B1 Antibodies) protects LDLR (show LDLR Antibodies) from degradation likely by preventing early binding of PCSK9 to LDLR (show LDLR Antibodies)
The absence of PCSK9 results in a sex- and tissue-specific subcellular distribution of the LDLR (show LDLR Antibodies) and VLDLR (show VLDLR Antibodies), which is determined by estradiol levels.
that ox-LDL receptor-1 (show OLR1 Antibodies) and PCSK9 positively influence each other's expression, especially during an inflammatory reaction
Data show that leptin (show LEP Antibodies) treatment suppresses proprotein convertase subtilisin/kexin type 9 (PCSK9) in male, but fails to suppress PCSK9 in female.
The Liver Clock Controls Cholesterol Homeostasis through Trib1 (show TRIB1 Antibodies) Protein-mediated Regulation of PCSK9/Low Density Lipoprotein Receptor (LDLR (show LDLR Antibodies)) Axis.
This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. The encoded protein is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. The protein may function as a proprotein convertase. This protein plays a role in cholesterol homeostasis and may have a role in the differentiation of cortical neurons. Mutations in this gene have been associated with a third form of autosomal dominant familial hypercholesterolemia (HCHOLA3).
proprotein convertase subtilisin/kexin type 9
, convertase subtilisin/kexin type 9 preproprotein
, neural apoptosis regulated convertase 1
, subtilisin/kexin-like protease PC9
, convertase subtilisin
, neural apoptosis-regulated convertase 1
, proprotein convertase 9
, proprotein convertase PC9
, proprotein convertase subtilisin/kexin type 9 preproprotein
, Proprotein convertase 9
, Subtilisin/kexin-like protease PC9